We are live on ! Find out more

Moderna

MRNA

Market cap $85.6B

214.47 USD

+6.50

3.13%

At close Updated Oct 28, 9:46 AM EDT

1 day

3.13%

5 days

-10.69%

1 month

8.71%

3 months

284.29%

6 months

354.96%

Year to date

594.98%

1 year

746.04%

5 years

-38.36%

10 years

1,053.06%

About: Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Employees: 4,700

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 51.1%

Neutral 25.6%

Negative 23.3%

Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid?

Merck & Co. NYSE: MRK and Moderna NASDAQ: MRNA just cleared a bar no cancer vaccine had cleared before. Their personalized melanoma vaccine succeeded in a Phase 3 trial.

Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid?

William Blair Takes a Shot at Moderna Stock: Downgrade to Market Perform After a 545% Run

Moderna Inc. (NASDAQ:MRNA) shares are trading lower Tuesday after William Blair downgraded the stock to Market Perform from Outperform on Monday, citing valuation concerns.

William Blair Takes a Shot at Moderna Stock: Downgrade to Market Perform After a 545% Run

Moderna Has Its Doubters. CEO Bancel Plans to Answer With a Cancer Shot.

Moderna CEO Stéphane Bancel says the biotech's competitive edge stems from its mRNA platform, likening it to software in Big Tech.

Moderna Has Its Doubters. CEO Bancel Plans to Answer With a Cancer Shot.

Bloomberg Markets and Finance

Moderna CEO Sees Cancer Vaccines Working Beyond Melanoma

Moderna CEO Stephane Bancel believes the personalized mRNA cancer vaccine being developed with Merck will work in a variety of tumors. Speaking with Romaine Bostick on "Bloomberg The Close," Bancel also says the recent data leak for the cancer vaccine candidate did not come from either Moderna or Merck.

Moderna CEO Sees Cancer Vaccines Working Beyond Melanoma

Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next

Moderna's stock has taken a big hit that could signal the end of this year's cancer vaccine-driven rally. It may not be too late to play the forces behind its rise.

Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next

Bloomberg Markets and Finance

Data about Merck and Moderna Melanoma Vaccine Leaks Out

Leaked data from Moderna and Merck's highly anticipated melanoma vaccine trial has led to a rare disconnect between doctors, who celebrated the result, and Wall Street, which sold off the stocks. Normally results of such pivotal drug studies are binary, with doctors, patients and investors all learning whether a novel medicine will make a meaningful difference in people's lives and forming the same conclusion.

Data about Merck and Moderna Melanoma Vaccine Leaks Out

Investors Business Daily

Moderna Recovers From 10% Dive, But Muted Expectations Haunt Cancer Vaccine

Moderna stock yo-yoed Monday on more muted expectations for its Merck-partnered cancer vaccine, INT.

Moderna Recovers From 10% Dive, But Muted Expectations Haunt Cancer Vaccine

The excitement around Moderna's cancer vaccine is cooling. Here's why.

Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker's experimental cancer treatment.

The excitement around Moderna's cancer vaccine is cooling. Here's why.

24/7 Wall Street

Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady

A closely tracked personalized melanoma vaccine met its main goal. Its effect on distant spread came in far smaller than an earlier study suggested in a late-stage trial.

Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady

Moderna Stock Saga: Leaked Data, a Panicked Influencer and Perfect Timing

Moderna Inc. (NASDAQ:MRNA) investors spent months treating the company's cancer vaccine as a potential cure. Last week, leaked trial data delivered a reality check.

Moderna Stock Saga: Leaked Data, a Panicked Influencer and Perfect Timing

See News Rankings

Price charts implemented using Lightweight Charts™